This story has been updated to include information about Twist Bioscience's filing for a stock offering worth up to $200 million.
NEW YORK – Twist Bioscience is looking to deliver new products based off its synthetic DNA manufacturing platform as well as new biopharma partnerships over the rest of fiscal year 2020.
The San Francisco-based firm will be expanding its product line in several directions, CEO and Cofounder Emily Leproust said on a conference call on Wednesday following the release of the firm's fiscal fourth quarter and full-year 2019 financial results.